

# The Farmabrazilis Infectious Disease Proposal

## Invitation

Farmabrazilis welcomes new partners to help advance this project. We will be glad to discuss different partnership formats to pursue common goals. Visit us at Stand 22 of the StopTB Forum in Rio de Janeiro, or write to: [alliances@farmabrazilis.org](mailto:alliances@farmabrazilis.org)

## Assets

Farmabrazilis has four valuable assets to share with partners.

- **Product:** P-MAPA is one of the few medicines with immunotherapeutic action in the pipeline today that, according to evidence, could help face such major challenges as TB or malaria.
- **Time savings:** P-MAPA has 17 years of development behind it, and is ready for clinical trials.
- **Cost savings:** Achieving the current stage of development of P-MAPA usually requires massive amounts of funds.
- **Expertise:** The Farmabrazilis team has developed the product and its production process, and can also provide assistance in planning and executing clinical trials.

## Terms of partnership

Farmabrazilis is open to partnerships with individuals, groups or institutions committed to improving public health in different parts of the world.

We expect our partners to agree to the Farmabrazilis basic policies. In particular, our licensing policy includes the possibility of royalty-exempt transference of technology in the case of neglected diseases and disadvantaged populations. This means that, in such cases, partners cannot sell the medicines or the technologies associated to them, nor gain any other direct or indirect benefits.